U.K. agency favors NHS coverage of Remicade for colitis

12/17/2008 | Reuters

The U.K.'s National Institute for Health and Clinical Excellence endorsed Schering-Plough's Remicade for National Health Service coverage as an alternative for patients with ulcerative colitis who do not respond to ciclosporin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC